Multiple Sclerosis

Latest News

Ozanimod Shows Sustained Efficacy in Long-term Study for Multiple Sclerosis Treatment
Ozanimod Shows Sustained Efficacy in Long-term Study for Multiple Sclerosis Treatment

March 11th 2024

Long-term data from the phase 3 DAYBREAK trial affirmed sustained efficacy of ozanimod for relapsing forms of multiple sclerosis, with a high amount of patients who were relapse-free at 6 years.

lexiconimages-stock.adobe.com
Pregnancy Interrupts Treatment for MS, Finds Real-World Study

March 7th 2024

Highly Effective Therapies Found Superior to Moderately Effective Therapies as First-Line Treatment in Pediatric MS
Highly Effective Therapies Found Superior to Moderately Effective Therapies as First-Line Treatment in Pediatric MS

March 6th 2024

Study Finds Monoclonal Antibody Exposure Does Not Negatively Affect Breastfed Infants of Mothers With MS
Study Finds Monoclonal Antibody Exposure Does Not Negatively Affect Breastfed Infants of Mothers With MS

March 4th 2024

Real-world Study Finds Fingolimod Leads to Better Clinical Outcomes but Higher Healthcare Costs in MS Patients
Real-world Study Finds Fingolimod Leads to Better Clinical Outcomes but Higher Healthcare Costs in MS Patients

February 9th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.